Cellspan oesophageal implant - Biostage

Drug Profile

Cellspan oesophageal implant - Biostage

Alternative Names: Cellspan-Paediatric-Oesophageal-Implant; Oesophageal stem cell implant - Biostage

Latest Information Update: 03 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biostage
  • Class Stem cell therapies
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal atresia; Oesophageal cancer
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Oesophageal cancer

Most Recent Events

  • 29 Mar 2018 Biostage receives SBIR grant from National Institute of Child Health and Human Development for Cellspan oesophageal implant development in esophageal atresia
  • 13 Mar 2018 Pharmacodynamics data from a preclinical study in Cancer released by Biostage
  • 08 Feb 2018 9232834 - no updates
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top